NEW YORK, Feb. 20 - Perlegen Sciences has signed a multi-year research collaboration with Unilever that will use the Affymetrix spinoff's whole genome-association technologies to develop new consumer products.
Terms of the agreement, announced today, call for Perlegen to pocket research funding, "research success payments," and royalties on consumer product sales. In addition, Perlegen will retain rights to develop potential therapeutic products based on the research results.
Unilever, founded in 1930, sells a variety of consumer goods from tea bags and ice cream to soaps and candies. It was not immediately clear what kinds of products the collaboration would develop, or in what way Perlegen's technology would be used. Officials at both companies did not immediately return telephone calls seeking comment.